BIOARTIFICIAL LIVERS FROM HEPATIC PROGENITOR CELLS
Project Number5R01DK052851-04
Contact PI/Project LeaderREID, LOLA M
Awardee OrganizationUNIV OF NORTH CAROLINA CHAPEL HILL
Description
Abstract Text
Rat liver contains progenitor cells located by each of the portal triads
and which produce daughter cells that mature through a unidirectional,
differentiation process ending at the central vein. Thus, the plates
of parenchymal cells within each acinus (in vivo) are lineages of
maturing liver cells with age-dependent size, ploidy, growth and
differentiative potential. We propose to use these progenitor cells,
purified by multiparametric fluorescence activated cell sorting, to
establish a bioartificial liver. The cells will be seeded into a hollow
fiber bioreactor, of novel design, and under defined ex vivo culture
conditions that are entirely or mostly serum-free, contain defined and
purified extracellular matrix components as substratum, and defined and
purified soluble signals (hormones, growth factors, nutrients).
Protocols have been developed, and antigenic profiles defined by which
to identify and isolate three subpopulations of hepatic progenitors and
two subpopulations of mature parenchymal cells using a combination of
panning and multiparametric fluorescence activated cell sorting (FACS):
hepatoblasts (pluripotent hepatic progenitors); committed biliary and
hepatocytic progenitors; periportal parenchymal cells (presumptive young
parenchyma); and 5) pericentral parenchymal cells (presumptive old
parenchyma). Also developed are in vivo bioassays for fate studies, ex
vivo conditions that permit cell expansion and others that drive
differentiation of each of the progenitor subpopulations. The rat
bioartificial liver will be established from each of the 5
subpopulations of maturationally staged parenchymal cells by seeding
them onto porous, biodegradable mircocarriers coated with matrix
components, into a novel form of hollow fiber bioreactor and under
appropriate ex vivo expansion conditions. A separate bioreactor for
feeder cells will be established and will contain two feeder cell types
found to yield paracrine signals that are strict requirements for growth
of the progenitors: 1) FACS-purified hemopoietic OCAP cells (myeloid
cells that bear an oval cell antigen 3+, OC3+) and the STO embryonic
stromal cell line, that has recently been found to replace primary
cultures of age- and liver-specific stromal feeder cells (from E14-E16
livers). The bioreactors with the feeder cells will be coupled in
tandem with the ones containing the hepatic progenitor cells; if the
factors produce by the feeders are too labile to survive the tandemly
connected bioreactors, the feeder cells will be treated with mitomycin
C and co-seeded into the same bioreactors with the hepatic progenitors.
The bioartifical livers and control monolayer cultures will be
characterized for fetal and adult liver-specific functions and for
hemopoietic markers by means of the Johnson and Johnson dry slide
assays, by immunochemistry, biochemical assays, molecular hybridization
assays and by flow cytometric analyses. In addition, the bioreactors
will be characterized non-invasively using nuclear magnetic resonance
and magnetic resonance imaging. The fates of the cells in the
bioreactors will be compared with those identified from in vivo
bioassays.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
848
DUNS Number
608195277
UEI
D3LHU66KBLD5
Project Start Date
24-June-1998
Project End Date
31-May-2003
Budget Start Date
01-June-2001
Budget End Date
31-May-2003
Project Funding Information for 2001
Total Funding
$314,694
Direct Costs
$217,781
Indirect Costs
$96,913
Year
Funding IC
FY Total Cost by IC
2001
National Institute of Diabetes and Digestive and Kidney Diseases
$314,694
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DK052851-04
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DK052851-04
Patents
No Patents information available for 5R01DK052851-04
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DK052851-04
Clinical Studies
No Clinical Studies information available for 5R01DK052851-04
News and More
Related News Releases
No news release information available for 5R01DK052851-04
History
No Historical information available for 5R01DK052851-04
Similar Projects
No Similar Projects information available for 5R01DK052851-04